Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00543439
Registration number
NCT00543439
Ethics application status
Date submitted
11/10/2007
Date registered
15/10/2007
Date last updated
11/01/2019
Titles & IDs
Public title
Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII
Query!
Scientific title
An Open-label Study To Evaluate Prophylaxis Treatment, And To Characterize The Efficacy, Safety, And Pharmacokinetics Of B-domain Deleted Recombinant Factor Viii Albumin Free (Moroctocog Alfa [Af-cc]) In Children With Hemophilia A
Query!
Secondary ID [1]
0
0
B1831001
Query!
Secondary ID [2]
0
0
3082B2-313
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hemophilia A
0
0
Query!
Condition category
Condition code
Blood
0
0
0
0
Query!
Clotting disorders
Query!
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - Moroctocog alfa (AF-CC)
Other interventions - Moroctocog alfa (AF-CC)
Experimental: 1 - On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
Experimental: 2 - Routine Prophylaxis Crossover
Other interventions: Moroctocog alfa (AF-CC)
On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
Other interventions: Moroctocog alfa (AF-CC)
Routine prophylaxis crossover:
45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Mean Annualized Bleed Rate (ABR) by Treatment: On Demand Cohort
Query!
Assessment method [1]
0
0
ABR for each participant was calculated as the number of bleeds requiring administration of moroctocog alfa (AF-CC) divided by the total therapy duration (in days), then multiplied by 365.25 (days in a year).
Query!
Timepoint [1]
0
0
Day 1 up to Month 6 (OD Cohort, OD Therapy, Period 1); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [1]
0
0
Mean Annualized Bleed Rate (ABR) by Treatment: Routine Prophylaxis Cohort
Query!
Assessment method [1]
0
0
ABR for each participant was calculated as the number of bleeds requiring administration of moroctocog alfa (AF-CC) divided by the total therapy duration (in days), then multiplied by 365.25 (days in a year).
Query!
Timepoint [1]
0
0
Day 1 up to Month 24 (RP Cohort, Period 1 and Period 2)
Query!
Secondary outcome [2]
0
0
Mean of Moroctocog Alfa (AF-CC) Infusions Administered To Treat Bleeding Episode: All Participants
Query!
Assessment method [2]
0
0
In this outcome measure, the mean of total number of moroctocog alfa (AF-CC) on-demand infusions administered to treat each bleeding episode was reported, regardless of participant cohort or period during which it occurred.
Query!
Timepoint [2]
0
0
Day 1 up to Month 24
Query!
Secondary outcome [3]
0
0
Number of Treated Bleeds Classified on Basis of Response to First Infusion of Moroctocog Alfa (AF-CC) as On-Demand Treatment: OD Therapy (OD and RP Cohort)
Query!
Assessment method [3]
0
0
Number (no.) of bleeds treated are reported on basis of response to first infusion of study drug, at 4-point scale: excellent, good, moderate, no response. Excellent:definite pain relief and/or improvement in bleeding signs within 8 hours (hr) after infusion, no additional infusion administered; Good:definite pain relief and/or improvement in bleeding signs within 8 hr after infusion, at least 1 additional infusion administered for complete resolution or with no additional infusion administered; Moderate:probable or slight improvement starting after 8 hr following infusion,at least 1 additional infusion administered for complete resolution; No Response: no improvement at all between infusions or during 24 hr interval following infusion or condition worsen. Bleeds for which response not recorded, reported as:Data Not Recorded. Total no. of first infusions may not be equal to total no. of bleeds if bleed was: missing start date/dose information or treated initially with non-study FVIII.
Query!
Timepoint [3]
0
0
Day 1 up to Month 24
Query!
Secondary outcome [4]
0
0
Number of Treated Spontaneous Bleeds by Time Interval Between Bleed Onset and Prior Moroctocog Alfa (AF-CC) Prophylaxis Dose: Routine Prophylaxis Therapy
Query!
Assessment method [4]
0
0
In this outcome measure number of treated spontaneous bleeds are reported according to the time interval between bleed onset and prior moroctocog alfa (AF-CC) routine prophylaxis dose. Following time intervals used to report this outcome measure: lesser than or equal to (<=) 24 hours, greater than (>) 24 hours to <=48 hours, >48 hours to <=72 hours, >72 hours. For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg" cumulative data for routine prophylaxis cohort (Day 1 up to Month 24, Period 1 and Period 2) and on demand cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [4]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [5]
0
0
Number of Participants Requiring Prophylaxis Regimen Escalation: Routine Prophylaxis Therapy
Query!
Assessment method [5]
0
0
During prophylaxis, criteria for prophylaxis regimen escalation are the occurrence, over a 4-week duration (and in the absence of a confirmed FVIII inhibitor), of (a) 2 or more spontaneous bleeds into a major joint and/or target joint, or (b) 3 or more spontaneous bleeds (consisting of joint bleeds and/or significant soft tissue/muscle or other site bleeds). If either criterion was met, the participant was escalated to a more intense prophylaxis regimen of 45 IU/kg, administered every other day. Participant who meet dose escalation criteria while on prophylaxis regimen of 45 IU/kg, were escalated to a higher intensity regimen designated by the investigator. Significant spontaneous bleeds were those that led to a transient or persistent loss of function. For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for RP cohort (Day 1 up to Month 24, Period 1 and Period 2) and OD cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [5]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [6]
0
0
Mean Routine Prophylaxis Dose (IU/kg) of Moroctocog Alfa (AF-CC) Received: Routine Prophylaxis Therapy
Query!
Assessment method [6]
0
0
Mean RP dose (by weight) for each participant was calculated as his total moroctocog alfa (AF-CC) consumption (in IU) divided by weight (in kg). For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for routine prophylaxis cohort (Day 1 up to Month 24, Period 1 and Period 2) and on demand cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [6]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [7]
0
0
Mean of Total Number Moroctocog Alfa (AF-CC) Infusions Received: Routine Prophylaxis Therapy
Query!
Assessment method [7]
0
0
In this outcome measure mean of total number of infusions of moroctocog alfa (AF-CC) received by participant is reported. For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for routine prophylaxis cohort (Day 1 up to Month 24, Period 1 and Period 2) and on demand cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [7]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [8]
0
0
Mean of Total Number of Days Participants Exposed to Moroctocog Alfa (AF-CC): Routine Prophylaxis Therapy
Query!
Assessment method [8]
0
0
For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for routine prophylaxis cohort (Day 1 up to Month 24, Period 1 and Period 2) and on demand cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [8]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [9]
0
0
Mean of Total Number of Infusions of Moroctocog Alfa (AF-CC) Received Per Week to Assess Compliance: Routine Prophylaxis Therapy
Query!
Assessment method [9]
0
0
Participants' compliance to their assigned prophylaxis regimen was measured by following: a) number of infusions received per week and b) dose received. In this outcome measure mean of total number of infusions of moroctocog alfa (AF-CC) received by participants per week is reported. For reporting arm: "Moroctocog alfa (AF-CC),OD and RP Cohort: RP Therapy 25 IU/kg" cumulative data for routine prophylaxis cohort (Day 1 up to Month 24, Period 1 and Period 2) and on demand cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [9]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [10]
0
0
Terminal Phase Half Life (t1/2) of Factor VIII (FVIII) Activity
Query!
Assessment method [10]
0
0
Plasma decay half-life is the time measured for the FVIII activity to decrease by one half.
Query!
Timepoint [10]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [11]
0
0
Clearance (CL) of Factor VIII Activity
Query!
Assessment method [11]
0
0
Clearance is a measure of the volume of plasma from which FVIII activity is removed per unit time. It was reported in units milliliter per hour per kilogram (mL/hr/kg).
Query!
Timepoint [11]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [12]
0
0
Incremental Recovery of Factor VIII Activity
Query!
Assessment method [12]
0
0
Incremental recovery was the increase in circulating FVIII activity for every international unit (IU) of moroctocog alfa (AF-CC) administered per kilogram of body weight of participant. It was measured in international units per deciliter per international units per kilogram ([IU/dL]/[IU/kg]).
Query!
Timepoint [12]
0
0
Day 1, Month 6
Query!
Secondary outcome [13]
0
0
Maximum Concentration of Factor VIII Activity
Query!
Assessment method [13]
0
0
Maximum concentration of FVIII activity was measured in international units per milliliter (IU/mL).
Query!
Timepoint [13]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [14]
0
0
Area Under the Curve From Time Zero to Extrapolated Infinite Time (AUCinf) of Factor VIII Activity
Query!
Assessment method [14]
0
0
Area under FVIII activity-time profile from time zero extrapolated to infinite time. AUCinf is reported in units: international units*hour per milliliter (IU*hour/mL).
Query!
Timepoint [14]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [15]
0
0
Area Under the Curve From Time Zero to Last Measurable Concentration (AUClast) of Factor VIII Activity
Query!
Assessment method [15]
0
0
Area under the FVIII activity -versus-time curve from time zero to the time of the last quantifiable concentration.
Query!
Timepoint [15]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [16]
0
0
Steady-State Volume of Distribution (Vss) of Factor VIII Activity
Query!
Assessment method [16]
0
0
Volume of distribution is defined as the theoretical volume in which the total amount of FVIII would need to be uniformly distributed to produce the observed plasma concentration of FVIII. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Query!
Timepoint [16]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [17]
0
0
Mean Residence Time (MRT) of Factor VIII Activity
Query!
Assessment method [17]
0
0
MRT was calculated as AUMCinf /AUCinf-TI/2, where AUMCinf is the area under the moment curve from time zero to infinity and TI is the duration of infusion.
Query!
Timepoint [17]
0
0
0.5, 8, 24, 28 and 32 hours post dose on Day 1
Query!
Secondary outcome [18]
0
0
Number of Participants With Treatment Emergent Adverse Events (AEs) According to Severity
Query!
Assessment method [18]
0
0
AE is untoward medical occurrence in clinical investigation participant administered product or medical device;event need not necessarily had causal relationship with treatment or usage.Treatment-emergent are events between first dose of study drug and up to 28 days after last dose of study drug (up to 25 months)that were absent before treatment or that worsened relative to pretreatment state.AEs were classified into following on basis of severity:1)mild = did not interfere with participant's usual function;2)moderate=interfered to some extent with participant's usual function;3)severe=interfered significantly with participant's usual function;4)life threatening=AE required discontinuation of study drug,participant was at immediate risk of death.All participants in study received AF-CC.AEs were not collected separately for each intervention for participants.All participants were properly combined for analysis,regardless of regimen were following at time,regardless of OD or RP cohort.
Query!
Timepoint [18]
0
0
Day 1 up to Month 25
Query!
Secondary outcome [19]
0
0
Number of Participants With Treatment-Related Adverse Events
Query!
Assessment method [19]
0
0
A treatment related AE is any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event had a causal relationship with the treatment or usage. All participants in the study received moroctocog alfa-(AF-CC). Adverse events were not collected separately for each intervention for the participants. All participants were properly combined for the analysis and was regardless of the regimen they were following at the time, and regardless of OD or RP cohort.
Query!
Timepoint [19]
0
0
Day 1 up to Month 25
Query!
Secondary outcome [20]
0
0
Number of Participants With Confirmed FVIII Inhibitor Development
Query!
Assessment method [20]
0
0
Confirmed FVIII inhibitors were defined as a neutralizing antibody to FVIII with a titer value of greater than or equal to (>=) 0.6 Bethesda units (BU) per millimeter in a sample assayed using the Nijmegen assay at the central laboratory.
Query!
Timepoint [20]
0
0
Day 1 up to Month 24
Query!
Secondary outcome [21]
0
0
Number of Participants With Incidence of Less Than Expected Therapeutic Effect (LETE): On Demand Therapy
Query!
Assessment method [21]
0
0
LETE occurs in OD setting if participant recorded 2 successive "No Response" (no improvement at all between infusions, or condition worsens) ratings after 2 successive infusions of study drug. Infusions must have been given within 24 hours (hr) of each other for treatment of same bleeding event in absence of confounding factors (known presence or subsequent identification of a FVIII inhibitor, known inadequate dose for type and/or severity of bleed in opinion of investigator, delay of >4 hr between onset of bleed to infusion, delay of >24 hr before administration of a follow-up infusion, known compromised study drug, faulty administration of study drug, participant had an underlying, predisposing condition responsible for bleed in opinion of investigator. For reporting arm: "Moroctocog alfa (AF-CC), OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for RP cohort (Day 1 up to Month 24, Period 1 and Period 2) and OD cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [21]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Day 1 up to Month 6 (OD Cohort, OD Therapy, Period 1); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Secondary outcome [22]
0
0
Number of Participants With Incidence of Less Than Expected Therapeutic Effect (LETE): Routine Prophylaxis Therapy
Query!
Assessment method [22]
0
0
LETE in prophylaxis setting if there was a spontaneous bleed within 48 hours after a regularly scheduled prophylactic dose of study drug (which was not used to treat a bleed) in the absence of confounding factors (known presence or subsequent identification of a FVIII inhibitor, known inadequate prophylactic dose [a dose less than that prescribed in participant's regimen], known lack of adherence to the prescribed prophylaxis regimen, bleed occurs in a target joint identified at the start of the study, known compromised study drug, faulty administration of study drug, participant had an underlying, predisposing condition responsible for the bleed in the opinion of the investigator. Therefore, LETE in the prophylaxis setting was the occurrence of a bleed. For reporting arm: "Moroctocog alfa (AF-CC), OD and RP Cohort: RP Therapy 25 IU/kg", cumulative data for RP cohort (Day 1 up to Month 24, Period 1 and Period 2) and OD cohort (Month 7 up to Month 18, Period 2) is reported.
Query!
Timepoint [22]
0
0
Day 1 up to Month 24 (RP Cohort, RP 25 IU/kg and 45 IU/kg, Period 1 and 2); Month 7 up to Month 18 (OD Cohort, RP 25 IU/kg, Period 2)
Query!
Eligibility
Key inclusion criteria
- Male subjects, aged less than 6 years, with moderately severe to severe hemophilia A.
- A negative FVIII inhibitor titer at screening, and a medical history negative for a
past FVIII inhibitor.
- At least 20 exposure days to any FVIII replacement product.
- Adequate hepatic and renal function
- CD4 count > 400 cells/uL, and if receiving antiviral therapy must be on a stable
regimen
Additional criteria for subjects participating in the PK assessment:
- Male subjects as described immediately above except they must have a FVIII Activity of
less than or equal to 1% confirmed by the central laboratory screening test
- Age < 6 years at time of PK assessment.
- The subject's size is sufficient to permit PK-related phlebotomy.
- The subject is able to comply with the procedures conducted during the PK assessment,
including a mandatory 72-hour washout period preceding the PK assessment.
Query!
Minimum age
6
Months
Query!
Query!
Maximum age
15
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- A history of FVIII inhibitor.
- Presence of a bleeding disorder in addition to hemophilia A.
- Treatment with any investigational drug or device within 30 days before the time of
signing the informed consent form.
- Major or orthopedic surgery planned to occur during the course of the study.
- Regular (e.g., daily, every other day) use of antifibrinolytic agents or medications
known to influence platelet function such as aspirin or certain nonsteroidal
anti-inflammatory drugs (NSAIDs), or regular, concomitant therapy with
immunomodulating drugs (e.g., intravenous immunoglobulin [IVIG], routine systemic
corticosteroids).
- Known hypersensitivity to hamster protein.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Crossover
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/12/2007
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
66
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Ohio
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Oregon
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Texas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Utah
Query!
Country [5]
0
0
Argentina
Query!
State/province [5]
0
0
Buenos Aires
Query!
Country [6]
0
0
Austria
Query!
State/province [6]
0
0
Wien
Query!
Country [7]
0
0
Colombia
Query!
State/province [7]
0
0
Bogota
Query!
Country [8]
0
0
Croatia
Query!
State/province [8]
0
0
Split
Query!
Country [9]
0
0
Jordan
Query!
State/province [9]
0
0
Irbid
Query!
Country [10]
0
0
Mexico
Query!
State/province [10]
0
0
Jalisco
Query!
Country [11]
0
0
Mexico
Query!
State/province [11]
0
0
Monterrey, Nuevo LEON
Query!
Country [12]
0
0
Mexico
Query!
State/province [12]
0
0
Nuevo LEON
Query!
Country [13]
0
0
New Zealand
Query!
State/province [13]
0
0
South Island
Query!
Country [14]
0
0
New Zealand
Query!
State/province [14]
0
0
Christchurch
Query!
Country [15]
0
0
Oman
Query!
State/province [15]
0
0
Muscat
Query!
Country [16]
0
0
Peru
Query!
State/province [16]
0
0
Arequipa
Query!
Country [17]
0
0
Poland
Query!
State/province [17]
0
0
Warszawa
Query!
Country [18]
0
0
Romania
Query!
State/province [18]
0
0
Bucuresti
Query!
Country [19]
0
0
Turkey
Query!
State/province [19]
0
0
Adana
Query!
Country [20]
0
0
Turkey
Query!
State/province [20]
0
0
Bornova
Query!
Country [21]
0
0
Turkey
Query!
State/province [21]
0
0
Istanbul
Query!
Country [22]
0
0
Turkey
Query!
State/province [22]
0
0
Kurupelit
Query!
Country [23]
0
0
Turkey
Query!
State/province [23]
0
0
Antalya
Query!
Country [24]
0
0
Turkey
Query!
State/province [24]
0
0
Izmir
Query!
Country [25]
0
0
Turkey
Query!
State/province [25]
0
0
Kayseri
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this research study is to determine the effectiveness, safety, and
pharmacokinetics (PK) of moroctocog alfa (AF-CC) in previously treated subjects, who are
younger than 6 years of age, with severe or moderately severe hemophilia A.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00543439
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00543439
Download to PDF